
In first open-label phase 3 data from the ADEPT program, KarXT cut hallucination and delusion scores in Alzheimer disease psychosis, with no new safety signals.
A meta-analysis exploring factors associated with quality of life in first-episode psychosis provides guidance and take-home points for clinicians.




